A Munich-area company specialising in messenger RNA (mRNA) technology has entered into a drug discovery deal with AstraZeneca Plc. Ethris GmbH will receive €25 million upfront, plus research funding, to develop therapies for respiratory diseases. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
